/PRNewswire/ Molecular Stethoscope, a leading precision medicine company pioneering the next-generation cell-free mRNA (cf-mRNA) liquid biopsy, announced.
Molecular Stethoscope Announces Completion and Publication of its Alzheimer s Disease Study in Science Advances
Study results highlight the Company s Next-Generation cf-mRNA Liquid Biopsy-Artificial Intelligence Technology Platform for characterization of Alzheimer s Disease
PALO ALTO, Calif., Dec. 14, 2020 /PRNewswire/ Molecular Stethoscope, Inc., a precision medicine biotechnology company, announces publication of a human proof-of-concept study for Alzheimer s Disease using its proprietary cell-free messenger RNA (cf-mRNA)-Artificial Intelligence Technology Platform. The study appeared in the December 2020 issue of the American Association for the Advancement of Science journal,
Science Advances. The Technology Platform s dynamic detection and monitoring of dysregulated genes and biological processes in Alzheimer s Disease provides a promising new approach to stratify patients and to follow disease course and targeted intervention, commented James Brewer, M.D., Ph.D., Dire